<< Back To Search

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT06119685
Age 18 +
Sex Both
Phase Phase 1, Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on combining different therapies to see how well they work together in managing the disease. Here are some key points about the study:
  • The study is unique because it combines multiple treatment strategies, which may enhance effectiveness compared to single therapies.
  • It involves a variety of treatment options, including targeted therapies and immunotherapies, which aim to boost the body's immune response against the cancer.
  • Patients will receive personalized treatment plans based on their specific health needs and the characteristics of their disease.
  • The study aims to evaluate the safety and effectiveness of these combined therapies, providing valuable information for future treatment options.
  • Participants will be closely monitored throughout the study to assess their response to the treatment and any side effects they may experience.
This research could lead to more effective treatment strategies and improved outcomes for patients facing this challenging condition.
Third Opinion AI Generated Synopsis

Trial Summary
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: